New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes

NCT05728931 | Active Not Recruiting

• 1 other identifier: 748
• Study Type: observational
• Target: 210
• Locations: 1 country
• Sites: 1

Brief Summary

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients. The investigators will use this project to better characterize AE and PNS patients to identify new diagnostic and prognostic biomarkers and develop new diagnostic tools.

Conditions

Paraneoplastic Neurological Syndrome; Autoimmune Encephalitis

Keywords

Paraneoplastic Neurological Syndrome; Autoimmune Encephalitis

Outcome Measures

Primary Outcomes (1)

• Description of new biomarkers

  Results of diagnostics tests for each patient, description of marking

  Baseline

Interventions

Test of biological samples BIOLOGICAL

Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient without antibodies known with neurological disorder and include in biobank of "centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes".

You may qualify if:

• patient with neurological disorder
• patient without antibody

You may not qualify if:

• patient with characterized antibody
• patient without neurological disorder

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes

Lyon, 69677, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples (0.5ml), CSF cerebrospinal Fluid (0.2ml), buffy coat (0.5ml), cells or tumors (FFPE block) have been collected in SNP collection

MeSH Terms

Conditions

Autoimmune Diseases of the Nervous System

Condition Hierarchy (Ancestors)

Nervous System Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2022
• First Posted: February 15, 2023
• Study Start: January 15, 2022
• Primary Completion: January 15, 2026
• Study Completion (Estimated): January 15, 2032
• Last Updated: February 15, 2023

Record last verified: 2023-02

Locations

FR (1)